Table 2.

HR and 95% CIs for 1 year cardiovascular (CV) morbidity and mortality of zofenopril versus placebo, other ACE inhibitors (ACEIs) versus placebo and zofenopril versus other ACEIs

	Zofenopril versus placebo (n=2759)		Other ACEIs vs placebo (n=1822)		Zofenopril vs other ACEIs (n=2679)
	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
Age (years)
≥65 (n=1543)	0.66 (0.51 to 0.85)	0.001	0.74 (0.51 to 1.07)	0.107	0.90 (0.66 to 1.21)	0.473
<65 (n=2084)	0.53 (0.38 to 0.73)	0.0001	0.78 (0.52 to 1.18)	0.236	0.67 (0.50 to 0.90)	0.008
Gender
Males (n=2733)	0.61 (0.48 to 0.78)	0.0001	0.83 (0.61 to 1.15)	0.265	0.73 (0.58 to 0.93)	0.012
Females (n=897)	0.60 (0.42 to 0.86)	0.005	0.70 (0.42 to 1.17)	0.174	0.86 (0.57 to 1.30)	0.479
Diabetes
Yes (n=1216)	0.61 (0.43 to 0.87)	0.007	0.67 (0.41 to 1.12)	0.127	0.91 (0.61 to 1.35)	0.631
No (n=2414)	0.60 (0.47 to 0.77)	0.0001	0.80 (0.58 to 1.11)	0.179	0.75 (0.59 to 0.95)	0.019
Hypertension
Yes (n=1880)	0.65 (0.49 to 0.86)	0.003	0.83 (0.57 to 1.21)	0.338	0.78 (0.60 to 1.01)	0.062
No (n=1662)	0.59 (0.44 to 0.79)	0.0001	0.76 (0.50 to 1.15)	0.194	0.77 (0.55 to 1.10)	0.150
CV risk factors
Yes (n=2962)	0.63 (0.51 to 0.78)	0.0001	0.78 (0.58 to 1.05)	0.107	0.81 (0.64 to 1.00)	0.060
No (n=668)	0.45 (0.26 to 0.78)	0.004	0.71 (0.36 to 1.41)	0.334	0.62 (0.37 to 1.06)	0.081

Data are shown for specific study subgroups. p Values refer to the statistical significance of OR.